JP2017516823A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017516823A5 JP2017516823A5 JP2016570986A JP2016570986A JP2017516823A5 JP 2017516823 A5 JP2017516823 A5 JP 2017516823A5 JP 2016570986 A JP2016570986 A JP 2016570986A JP 2016570986 A JP2016570986 A JP 2016570986A JP 2017516823 A5 JP2017516823 A5 JP 2017516823A5
- Authority
- JP
- Japan
- Prior art keywords
- dgla
- disease
- pharmaceutical composition
- skin
- acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- HOBAELRKJCKHQD-UHFFFAOYSA-N (8Z,11Z,14Z)-8,11,14-eicosatrienoic acid Natural products CCCCCC=CCC=CCC=CCCCCCCC(O)=O HOBAELRKJCKHQD-UHFFFAOYSA-N 0.000 claims description 68
- HOBAELRKJCKHQD-QNEBEIHSSA-N dihomo-γ-linolenic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/CCCCCCC(O)=O HOBAELRKJCKHQD-QNEBEIHSSA-N 0.000 claims description 68
- 239000000126 substance Substances 0.000 claims description 2
- 235000021298 Dihomo-γ-linolenic acid Nutrition 0.000 claims 67
- 239000008194 pharmaceutical composition Substances 0.000 claims 26
- 235000014113 dietary fatty acids Nutrition 0.000 claims 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 13
- 229930195729 fatty acid Natural products 0.000 claims 13
- 239000000194 fatty acid Substances 0.000 claims 13
- 150000004665 fatty acids Chemical class 0.000 claims 13
- 239000000203 mixture Substances 0.000 claims 12
- 239000002775 capsule Substances 0.000 claims 10
- 201000010099 disease Diseases 0.000 claims 8
- 208000017520 skin disease Diseases 0.000 claims 8
- 206010047302 ventricular tachycardia Diseases 0.000 claims 8
- 206010061592 cardiac fibrillation Diseases 0.000 claims 7
- 230000002600 fibrillogenic effect Effects 0.000 claims 7
- XSXIVVZCUAHUJO-AVQMFFATSA-N (11e,14e)-icosa-11,14-dienoic acid Chemical compound CCCCC\C=C\C\C=C\CCCCCCCCCC(O)=O XSXIVVZCUAHUJO-AVQMFFATSA-N 0.000 claims 6
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 claims 6
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 claims 6
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 claims 6
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 claims 6
- 235000021297 Eicosadienoic acid Nutrition 0.000 claims 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims 6
- 206010019280 Heart failures Diseases 0.000 claims 6
- 239000005642 Oleic acid Substances 0.000 claims 6
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 claims 6
- 208000003734 Supraventricular Tachycardia Diseases 0.000 claims 6
- 206010012601 diabetes mellitus Diseases 0.000 claims 6
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 claims 6
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims 6
- 208000035475 disorder Diseases 0.000 claims 5
- IQLUYYHUNSSHIY-HZUMYPAESA-N eicosatetraenoic acid Chemical compound CCCCCCCCCCC\C=C\C=C\C=C\C=C\C(O)=O IQLUYYHUNSSHIY-HZUMYPAESA-N 0.000 claims 5
- 235000021313 oleic acid Nutrition 0.000 claims 5
- 208000002874 Acne Vulgaris Diseases 0.000 claims 4
- 206010003658 Atrial Fibrillation Diseases 0.000 claims 4
- 108010010803 Gelatin Proteins 0.000 claims 4
- 208000030673 Homozygous familial hypercholesterolemia Diseases 0.000 claims 4
- 208000035150 Hypercholesterolemia Diseases 0.000 claims 4
- 206010030113 Oedema Diseases 0.000 claims 4
- 206010045261 Type IIa hyperlipidaemia Diseases 0.000 claims 4
- 206010047281 Ventricular arrhythmia Diseases 0.000 claims 4
- 206010000496 acne Diseases 0.000 claims 4
- 208000029078 coronary artery disease Diseases 0.000 claims 4
- 239000008273 gelatin Substances 0.000 claims 4
- 229920000159 gelatin Polymers 0.000 claims 4
- 235000019322 gelatine Nutrition 0.000 claims 4
- 235000011852 gelatine desserts Nutrition 0.000 claims 4
- 208000017169 kidney disease Diseases 0.000 claims 4
- 201000006370 kidney failure Diseases 0.000 claims 4
- 230000000306 recurrent effect Effects 0.000 claims 4
- 208000003663 ventricular fibrillation Diseases 0.000 claims 4
- 208000024172 Cardiovascular disease Diseases 0.000 claims 3
- 208000031226 Hyperlipidaemia Diseases 0.000 claims 3
- 206010063985 Phytosterolaemia Diseases 0.000 claims 3
- 201000004681 Psoriasis Diseases 0.000 claims 3
- 208000010378 Pulmonary Embolism Diseases 0.000 claims 3
- 208000025747 Rheumatic disease Diseases 0.000 claims 3
- 208000002227 Sitosterolemia Diseases 0.000 claims 3
- 230000001154 acute effect Effects 0.000 claims 3
- 239000012530 fluid Substances 0.000 claims 3
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 3
- 206010002383 Angina Pectoris Diseases 0.000 claims 2
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims 2
- 206010003267 Arthritis reactive Diseases 0.000 claims 2
- 201000001320 Atherosclerosis Diseases 0.000 claims 2
- 206010003662 Atrial flutter Diseases 0.000 claims 2
- 206010005003 Bladder cancer Diseases 0.000 claims 2
- 206010007559 Cardiac failure congestive Diseases 0.000 claims 2
- 206010011803 Cystocele Diseases 0.000 claims 2
- 206010051055 Deep vein thrombosis Diseases 0.000 claims 2
- 201000004624 Dermatitis Diseases 0.000 claims 2
- 206010012438 Dermatitis atopic Diseases 0.000 claims 2
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims 2
- 206010052337 Diastolic dysfunction Diseases 0.000 claims 2
- 206010013786 Dry skin Diseases 0.000 claims 2
- 208000032928 Dyslipidaemia Diseases 0.000 claims 2
- 206010014522 Embolism venous Diseases 0.000 claims 2
- 208000007530 Essential hypertension Diseases 0.000 claims 2
- 208000001640 Fibromyalgia Diseases 0.000 claims 2
- 201000005569 Gout Diseases 0.000 claims 2
- 206010020772 Hypertension Diseases 0.000 claims 2
- 206010021639 Incontinence Diseases 0.000 claims 2
- 208000004575 Infectious Arthritis Diseases 0.000 claims 2
- 208000005615 Interstitial Cystitis Diseases 0.000 claims 2
- 208000017170 Lipid metabolism disease Diseases 0.000 claims 2
- 208000001145 Metabolic Syndrome Diseases 0.000 claims 2
- 208000000693 Neurogenic Urinary Bladder Diseases 0.000 claims 2
- 206010029279 Neurogenic bladder Diseases 0.000 claims 2
- 208000008589 Obesity Diseases 0.000 claims 2
- 241000736199 Paeonia Species 0.000 claims 2
- 235000006484 Paeonia officinalis Nutrition 0.000 claims 2
- 208000003251 Pruritus Diseases 0.000 claims 2
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims 2
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims 2
- 206010064911 Pulmonary arterial hypertension Diseases 0.000 claims 2
- 208000001647 Renal Insufficiency Diseases 0.000 claims 2
- 208000004717 Ruptured Aneurysm Diseases 0.000 claims 2
- 208000007718 Stable Angina Diseases 0.000 claims 2
- 208000006011 Stroke Diseases 0.000 claims 2
- 208000001871 Tachycardia Diseases 0.000 claims 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 claims 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 2
- 208000012931 Urologic disease Diseases 0.000 claims 2
- 206010047249 Venous thrombosis Diseases 0.000 claims 2
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims 2
- 206010000891 acute myocardial infarction Diseases 0.000 claims 2
- 230000003712 anti-aging effect Effects 0.000 claims 2
- 206010003119 arrhythmia Diseases 0.000 claims 2
- 230000006793 arrhythmia Effects 0.000 claims 2
- 201000008937 atopic dermatitis Diseases 0.000 claims 2
- 230000000747 cardiac effect Effects 0.000 claims 2
- 208000020832 chronic kidney disease Diseases 0.000 claims 2
- 230000037336 dry skin Effects 0.000 claims 2
- 230000001747 exhibiting effect Effects 0.000 claims 2
- 208000010706 fatty liver disease Diseases 0.000 claims 2
- 230000036074 healthy skin Effects 0.000 claims 2
- 208000019622 heart disease Diseases 0.000 claims 2
- 208000006750 hematuria Diseases 0.000 claims 2
- 208000006575 hypertriglyceridemia Diseases 0.000 claims 2
- 230000000302 ischemic effect Effects 0.000 claims 2
- 208000019267 mild heart failure Diseases 0.000 claims 2
- 208000010125 myocardial infarction Diseases 0.000 claims 2
- 235000020824 obesity Nutrition 0.000 claims 2
- 201000008482 osteoarthritis Diseases 0.000 claims 2
- 230000001314 paroxysmal effect Effects 0.000 claims 2
- 230000003711 photoprotective effect Effects 0.000 claims 2
- 230000036470 plasma concentration Effects 0.000 claims 2
- 208000030761 polycystic kidney disease Diseases 0.000 claims 2
- 208000017497 prostate disease Diseases 0.000 claims 2
- 230000004224 protection Effects 0.000 claims 2
- 208000002815 pulmonary hypertension Diseases 0.000 claims 2
- 230000005855 radiation Effects 0.000 claims 2
- 208000002574 reactive arthritis Diseases 0.000 claims 2
- 208000023504 respiratory system disease Diseases 0.000 claims 2
- 201000001223 septic arthritis Diseases 0.000 claims 2
- 208000010110 spontaneous platelet aggregation Diseases 0.000 claims 2
- 230000006794 tachycardia Effects 0.000 claims 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims 2
- 208000014001 urinary system disease Diseases 0.000 claims 2
- 208000019206 urinary tract infection Diseases 0.000 claims 2
- 208000019553 vascular disease Diseases 0.000 claims 2
- 208000004043 venous thromboembolism Diseases 0.000 claims 2
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 claims 1
- 229940084778 1,4-sorbitan Drugs 0.000 claims 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims 1
- 208000009304 Acute Kidney Injury Diseases 0.000 claims 1
- 206010007558 Cardiac failure chronic Diseases 0.000 claims 1
- 206010065929 Cardiovascular insufficiency Diseases 0.000 claims 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims 1
- 208000019693 Lung disease Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 208000000112 Myalgia Diseases 0.000 claims 1
- 206010035664 Pneumonia Diseases 0.000 claims 1
- 208000007048 Polymyalgia Rheumatica Diseases 0.000 claims 1
- 208000011191 Pulmonary vascular disease Diseases 0.000 claims 1
- 208000033626 Renal failure acute Diseases 0.000 claims 1
- 206010057190 Respiratory tract infections Diseases 0.000 claims 1
- 208000026723 Urinary tract disease Diseases 0.000 claims 1
- 206010047370 Vesicoureteric reflux Diseases 0.000 claims 1
- 206010052428 Wound Diseases 0.000 claims 1
- 208000027418 Wounds and injury Diseases 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 201000011040 acute kidney failure Diseases 0.000 claims 1
- 230000001746 atrial effect Effects 0.000 claims 1
- 235000019197 fats Nutrition 0.000 claims 1
- 210000002837 heart atrium Anatomy 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 239000000787 lecithin Substances 0.000 claims 1
- 235000010445 lecithin Nutrition 0.000 claims 1
- 229940067606 lecithin Drugs 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 229940057917 medium chain triglycerides Drugs 0.000 claims 1
- 239000008213 purified water Substances 0.000 claims 1
- 208000017443 reproductive system disease Diseases 0.000 claims 1
- 230000000552 rheumatic effect Effects 0.000 claims 1
- 150000005846 sugar alcohols Chemical class 0.000 claims 1
- 210000000115 thoracic cavity Anatomy 0.000 claims 1
- 239000004408 titanium dioxide Substances 0.000 claims 1
- 230000002485 urinary effect Effects 0.000 claims 1
- 210000001635 urinary tract Anatomy 0.000 claims 1
- 201000008618 vesicoureteral reflux Diseases 0.000 claims 1
- 208000031355 vesicoureteral reflux 1 Diseases 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
- NPAKNKYSJIDKMW-UHFFFAOYSA-N carvedilol Chemical compound COC1=CC=CC=C1OCCNCC(O)COC1=CC=CC2=NC3=CC=C[CH]C3=C12 NPAKNKYSJIDKMW-UHFFFAOYSA-N 0.000 description 2
- 229960004195 carvedilol Drugs 0.000 description 2
- 238000013480 data collection Methods 0.000 description 2
- SONNWYBIRXJNDC-VIFPVBQESA-N phenylephrine Chemical compound CNC[C@H](O)C1=CC=CC(O)=C1 SONNWYBIRXJNDC-VIFPVBQESA-N 0.000 description 2
- 229960001802 phenylephrine Drugs 0.000 description 2
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 230000004872 arterial blood pressure Effects 0.000 description 1
- 238000013500 data storage Methods 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000011699 spontaneously hypertensive rat Methods 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462007752P | 2014-06-04 | 2014-06-04 | |
| US62/007,752 | 2014-06-04 | ||
| US201462058469P | 2014-10-01 | 2014-10-01 | |
| US62/058,469 | 2014-10-01 | ||
| PCT/EP2015/062518 WO2015185698A1 (en) | 2014-06-04 | 2015-06-04 | Pharmaceutical compositions comprising dgla and use of same |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020003665A Division JP2020090508A (ja) | 2014-06-04 | 2020-01-14 | Ｄｇｌａを含む薬学的組成物及びその使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017516823A JP2017516823A (ja) | 2017-06-22 |
| JP2017516823A5 true JP2017516823A5 (https=) | 2018-09-20 |
Family
ID=53298373
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016570986A Pending JP2017516823A (ja) | 2014-06-04 | 2015-06-04 | Ｄｇｌａを含む薬学的組成物及びその使用 |
| JP2020003665A Withdrawn JP2020090508A (ja) | 2014-06-04 | 2020-01-14 | Ｄｇｌａを含む薬学的組成物及びその使用 |
| JP2022030554A Pending JP2022071061A (ja) | 2014-06-04 | 2022-03-01 | Ｄｇｌａを含む薬学的組成物及びその使用 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020003665A Withdrawn JP2020090508A (ja) | 2014-06-04 | 2020-01-14 | Ｄｇｌａを含む薬学的組成物及びその使用 |
| JP2022030554A Pending JP2022071061A (ja) | 2014-06-04 | 2022-03-01 | Ｄｇｌａを含む薬学的組成物及びその使用 |
Country Status (17)
| Country | Link |
|---|---|
| US (9) | US9682055B2 (https=) |
| EP (2) | EP3692986A1 (https=) |
| JP (3) | JP2017516823A (https=) |
| KR (1) | KR102391827B1 (https=) |
| CN (1) | CN107072959A (https=) |
| AU (2) | AU2015270418B2 (https=) |
| BR (1) | BR112016028518A2 (https=) |
| CA (1) | CA2953633A1 (https=) |
| ES (1) | ES2784240T3 (https=) |
| IL (2) | IL249364B (https=) |
| MA (1) | MA52644A (https=) |
| MX (2) | MX375328B (https=) |
| PH (1) | PH12016502530A1 (https=) |
| RU (2) | RU2020101477A (https=) |
| SG (2) | SG11201610207WA (https=) |
| WO (1) | WO2015185698A1 (https=) |
| ZA (2) | ZA201708681B (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0907413D0 (en) | 2009-04-29 | 2009-06-10 | Equateq Ltd | Novel methods |
| JP2016538288A (ja) | 2013-11-15 | 2016-12-08 | ディグニティ サイエンシス リミテッド | 多価不飽和ヒドロキシ脂肪酸の薬学的に許容される塩 |
| US9682055B2 (en) | 2014-06-04 | 2017-06-20 | Dignity Sciences Limted | Pharmaceutical compositions comprising DGLA and use of same |
| MA47141A (fr) | 2015-05-13 | 2019-11-06 | Ds Biopharma Ltd | Compositions comprenant du15-oxo-epa ou du 15-oxo-dgla et leurs procédés de préparation et d'utilisation |
| CA3027867A1 (en) * | 2016-01-07 | 2017-07-13 | Ds Biopharma Limited | Pharmaceutical compositions comprising dgla and use of same |
| CN110996937A (zh) * | 2017-05-19 | 2020-04-10 | Ds生物制药有限公司 | 包含dgla的药物组合物及其用途 |
| JP7500037B2 (ja) * | 2019-07-24 | 2024-06-17 | 国立大学法人 東京大学 | 血中尿酸値低下剤及び血中尿酸値低下用食品組成物 |
| US20210315851A1 (en) | 2020-04-03 | 2021-10-14 | Afimmune Limited | Compositions comprising 15-hepe and methods of treating or preventing hematologic disorders, and/or related diseases |
Family Cites Families (94)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5264452A (en) | 1975-11-18 | 1977-05-27 | Nippon Suisan Kaisha Ltd | Method of producing processed fish meat |
| JPS5820575B2 (ja) | 1975-11-27 | 1983-04-23 | 日本水産株式会社 | スイサンカコウヒンノセイゾウホウ |
| US4273763A (en) | 1978-01-23 | 1981-06-16 | Efamol Limited | Pharmaceutical and dietary compositions |
| IE47777B1 (en) * | 1978-01-23 | 1984-06-13 | Efamol Ltd | Pharmaceutical and dietary composition comprising gamma-linolenic acids |
| US4444755A (en) | 1978-01-23 | 1984-04-24 | Efamol Limited | Treatment for skin disorders |
| DE2967049D1 (en) | 1978-04-11 | 1984-07-19 | Efamol Ltd | Pharmaceutical and dietary composition comprising gamma-linolenic acids |
| IE49783B1 (en) * | 1979-05-18 | 1985-12-11 | Efamol Ltd | Pharmaceutical and dietary composition comprising epsilon-linolenic acids |
| IE51145B1 (en) | 1980-03-07 | 1986-10-15 | Efamol Ltd | Pharmaceutical and dietary compositions |
| IE53332B1 (en) | 1980-03-14 | 1988-10-26 | Efamol Ltd | Pharmaceutical compositions |
| US5324748A (en) | 1981-07-14 | 1994-06-28 | Efamol Limited | Method for enhancement of 1-series PG production |
| DE3363567D1 (en) | 1982-03-01 | 1986-06-26 | Efamol Ltd | Pharmaceutical and dietary composition |
| DE3366838D1 (en) | 1982-03-01 | 1986-11-20 | Efamol Ltd | Pharmaceutical composition |
| EP0087865B1 (en) | 1982-03-01 | 1986-10-01 | Efamol Limited | Pharmaceutical composition |
| IE54795B1 (en) | 1982-04-29 | 1990-02-14 | Efamol Ltd | Pharmaceutical composition |
| GB8302708D0 (en) * | 1983-02-01 | 1983-03-02 | Efamol Ltd | Pharmaceutical and dietary composition |
| GB8319073D0 (en) | 1983-07-14 | 1983-08-17 | Efamol Ltd | Fatty acid compositions |
| GB8326130D0 (en) | 1983-09-29 | 1983-11-02 | Efamol Ltd | Topical preparations containing tars and fatty acids |
| GB8420771D0 (en) | 1984-08-15 | 1984-09-19 | Efamol Ltd | Treatment of skin disorders |
| GB8425006D0 (en) | 1984-10-03 | 1984-11-07 | Efamol Ltd | Composition of copper/fatty acids |
| GB8506027D0 (en) | 1985-03-08 | 1985-04-11 | Efamol Ltd | Pharmaceutical & dietary compositions |
| GB8522670D0 (en) | 1985-09-13 | 1985-10-16 | Efamol Ltd | Drug treatments |
| GB8524275D0 (en) | 1985-10-02 | 1985-11-06 | Efamol Ltd | Pharmaceutical & dietary compositions |
| US5198468A (en) | 1987-06-24 | 1993-03-30 | Efamol Holdings Plc | Essential fatty acid composition |
| EP0309086A1 (en) | 1987-09-07 | 1989-03-29 | Efamol Holdings Plc | Treatment of male pattern baldness and of unwanted hair growth |
| GB8729153D0 (en) | 1987-12-14 | 1988-01-27 | Efamol Ltd | Fatty acid compositions |
| US5352700A (en) | 1988-01-14 | 1994-10-04 | Anders Frithz | Use of essential fatty acids for the preparation of a drug for the treatment of infantile seborrheic eczema |
| GB8806737D0 (en) | 1988-03-22 | 1988-04-20 | Efamol Holdings | Therapeutic composition & method |
| CA1334002C (en) | 1988-09-28 | 1995-01-17 | Barry D. Sears | Essential fatty acid compositions and methods for the modulation of prostaglandin levels in mammals |
| US6140304A (en) | 1988-09-28 | 2000-10-31 | Eicotech Corporation | Method of and nutritional and pharmaceutical compositions for reduction of hyperinsulinemia |
| GB8916734D0 (en) * | 1989-07-21 | 1989-09-06 | Efamol Holdings | Pharmaceutical and dietary uses of fatty acids |
| GB8918294D0 (en) | 1989-08-10 | 1989-09-20 | Efamol Holdings | Pharmaceutical compositions |
| GB8920228D0 (en) | 1989-09-07 | 1989-10-18 | Efamol Holdings | Fatty acid therapy |
| JPH04290820A (ja) | 1991-03-18 | 1992-10-15 | Idemitsu Petrochem Co Ltd | 皮膚病犬の治療方法とその薬剤 |
| GB9111900D0 (en) * | 1991-06-03 | 1991-07-24 | Efamol Holdings | Fatty acid compositions |
| GB9112052D0 (en) * | 1991-06-05 | 1991-07-24 | Efamol Holdings | Fatty acid treatment |
| JP3354581B2 (ja) | 1991-09-30 | 2002-12-09 | サントリー株式会社 | ジホモ−γ−リノレン酸及びこれを含有する脂質の製造方法 |
| GB9211229D0 (en) | 1992-05-27 | 1992-07-08 | Efamol Holdings | Fatty acid treatment |
| US5888541A (en) | 1992-08-21 | 1999-03-30 | Scotia Holdings Plc | Fatty acid treatment |
| GB9217780D0 (en) | 1992-08-21 | 1992-10-07 | Efamol Holdings | Fatty acid treatment |
| FI101039B (fi) | 1992-10-09 | 1998-04-15 | Eeva Kristoffersson | Menetelmä lääkepellettien valmistamiseksi |
| DE4238869C2 (de) | 1992-11-18 | 1994-09-08 | Wogepharm Gmbh | Mittel zur Behandlung des atopischen Ekzems und anderer entzündlicher Hautkrankheiten |
| GB9301446D0 (en) | 1993-01-26 | 1993-03-17 | Scotia Holdings Plc | Internal radiation damage |
| AU683027B2 (en) * | 1993-01-27 | 1997-10-30 | Scotia Holdings Plc | Triglycerides |
| CA2119000A1 (en) | 1993-03-19 | 1994-09-20 | David Frederick Horrobin | Formulation for use in smokers |
| JPH09505562A (ja) * | 1993-10-01 | 1997-06-03 | アール．ピー．シェーラー コーポレイション | 香料を小分けして提供する方法および組成物 |
| GB9403855D0 (en) | 1994-03-01 | 1994-04-20 | Scotia Holdings Plc | Fatty acid derivatives |
| US5789441A (en) | 1996-02-15 | 1998-08-04 | Virocell Inc. | Leukotriene B4 as an antiviral and anti-neoplastic agent |
| GB9621373D0 (en) | 1996-10-14 | 1996-12-04 | Scotia Holdings Plc | Fatty acid treatment |
| GB9710351D0 (en) | 1997-05-20 | 1997-07-16 | Scotia Holdings Plc | Glucosamine fatty acids |
| GB9715444D0 (en) * | 1997-07-22 | 1997-09-24 | Scotia Holdings Plc | Therapeutic and dietary compositions |
| JP2000191525A (ja) | 1998-12-25 | 2000-07-11 | Nof Corp | 皮膚外用剤組成物 |
| GB9916536D0 (en) | 1999-07-14 | 1999-09-15 | Scarista Limited | Nutritional or pharmaceutical compositions |
| DK1072198T3 (da) * | 1999-07-28 | 2008-09-22 | Swiss Caps Rechte & Lizenzen | Præparat til anvendelse som medikament og/eller ernæringstilskud |
| EP1762557B1 (en) | 2000-02-16 | 2011-04-06 | The Brigham And Women's Hospital, Inc. | Aspirin-triggered lipid mediators |
| GB0016045D0 (en) | 2000-06-29 | 2000-08-23 | Laxdale Limited | Therapeutic combinations of fatty acids |
| JP2002047176A (ja) * | 2000-08-04 | 2002-02-12 | Idemitsu Technofine Co Ltd | ＩｇＥ産生抑制剤 |
| US20020188024A1 (en) | 2000-08-23 | 2002-12-12 | Chilton Floyd H. | Fatty acid-containing emulsion with increased bioavailability |
| US20040043013A1 (en) | 2000-12-28 | 2004-03-04 | Mccleary Edward Larry | Metabolic uncoupling therapy |
| DE10121252A1 (de) | 2001-04-30 | 2002-11-07 | Christos C Zouboulis | Behandlung der Akne |
| ATE291910T1 (de) | 2001-05-30 | 2005-04-15 | Laxdale Ltd | Verwendung von coenzym q (ubiquinone) und eikosapentaensäure (epa) für die behandlung von non-hodgkin's lymphoma und psychiatrischen oder neurologischen erkrankungen |
| JP2003155233A (ja) | 2001-11-16 | 2003-05-27 | Idemitsu Technofine Co Ltd | 塗布剤 |
| AU2003299034A1 (en) | 2002-09-20 | 2004-04-08 | Griscom Bettle Iii | Transdermal compositions |
| KR20050083960A (ko) | 2002-11-22 | 2005-08-26 | 닛폰 스이산 가부시키가이샤 | 고도 불포화 지방산, 그 염, 또는 그 에스테르를 함유하는외용 조성물 |
| US20050032757A1 (en) * | 2003-08-06 | 2005-02-10 | Cho Suk H. | Nutritional supplements |
| JP2005179211A (ja) | 2003-12-17 | 2005-07-07 | Idemitsu Kosan Co Ltd | 皮膚外用剤組成物 |
| EP1711173A2 (en) | 2003-12-31 | 2006-10-18 | Igennus Limited | Formulation containing an eicosapentaenoic acid or an ester thereof and a triterpene or ester thereof |
| AU2005262392A1 (en) | 2004-07-01 | 2006-01-19 | Johnson & Johnson Vision Care, Inc. | Compositions and methods for treating eye disorders and conditions |
| US7666447B2 (en) * | 2004-10-08 | 2010-02-23 | Pharmanutrients | Compositions including Krill extracts and conjugated linoleic acid and methods of using same |
| US7893106B2 (en) | 2004-11-19 | 2011-02-22 | Martek Biosciences, Corporation | Oxylipins from stearidonic acid and γ-linolenic acid and methods of making and using the same |
| JP5546087B2 (ja) | 2005-02-14 | 2014-07-09 | サントリーホールディングス株式会社 | 皮膚疾患経口治療または予防剤 |
| JP2006306812A (ja) | 2005-04-28 | 2006-11-09 | Suntory Ltd | 好酸球浸潤抑制剤 |
| EP3581178B1 (en) | 2005-02-14 | 2023-08-30 | Suntory Holdings Limited | Composition containing dihomo-(gamma)-linolenic acid (dgla) as active ingredient |
| US7485323B2 (en) | 2005-05-31 | 2009-02-03 | Gelita Ag | Process for making a low molecular weight gelatine hydrolysate and gelatine hydrolysate compositions |
| TW200711649A (en) | 2005-06-17 | 2007-04-01 | Combinatorx Inc | Combination therapy for the treatment of immunoinflammatory disorders |
| JP5101894B2 (ja) | 2007-01-15 | 2012-12-19 | サントリーホールディングス株式会社 | 高度不飽和脂肪酸及びこれを含有する脂質の製造方法 |
| ITMI20070555A1 (it) | 2007-03-21 | 2007-06-20 | Giuliani Spa | Composizione provvista di attivita' di inibizione sulla 5 alfa-reduttasi |
| WO2009130291A2 (de) | 2008-04-25 | 2009-10-29 | Basf Plant Science Gmbh | Pflanzensamenöl |
| GB0907413D0 (en) | 2009-04-29 | 2009-06-10 | Equateq Ltd | Novel methods |
| CA2690488C (en) * | 2010-01-19 | 2013-06-11 | Accucaps Industries Limited | Pharmaceutical formulations of naproxen for soft gel encapsulation and combinations thereof |
| GB201001345D0 (en) | 2010-01-27 | 2010-03-17 | Equateq Ltd | Process for preparing and purifying fatty acids |
| AU2011349718B2 (en) | 2010-12-21 | 2017-02-09 | Nestec S.A. | Methods and compositions for preventing and treating osteoarthritis |
| US8293790B2 (en) | 2011-10-19 | 2012-10-23 | Dignity Sciences Limited | Pharmaceutical compositions comprising DGLA and benzoyl peroxide and methods of use thereof |
| RU2014119948A (ru) | 2011-10-19 | 2015-11-27 | Дигнити Сайенсиз Лимитед | ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ, СОДЕРЖАЩИЕ DGLA И/ИЛИ 15-HETrE, И СПОСОБЫ ИХ ПРИМЕНЕНИЯ |
| JP2015500639A (ja) | 2011-11-29 | 2015-01-08 | ディグニティ サイエンシス リミテッド | ２０−炭素脂肪酸を含む組成物ならびにその製造方法および使用方法 |
| RS57777B1 (sr) | 2012-01-06 | 2018-12-31 | Omthera Pharmaceuticals Inc | Dpa-obogaćene kompozicije omega-3 polinezasićenih masnih kiselina u obliku slobodne kiseline |
| US20120264705A1 (en) | 2012-01-26 | 2012-10-18 | Dignity Sciences Limited | Antimicrobial compositions comprising 15-hetre and methods of use thereof |
| US20130267598A1 (en) | 2012-02-23 | 2013-10-10 | Dignity Sciences Limited | Pharmaceutical compositions comprising dgla, 15-ohepa, and/or 15-hetre and methods of reducing sebum production using same |
| WO2013150386A2 (en) * | 2012-04-04 | 2013-10-10 | Pronova Biopharma Norge As | Compositions comprising omega-3 fatty acids and vitamin d for acne vulgaris and/or eczema, and methods and uses thereof |
| GB2504061A (en) * | 2012-05-25 | 2014-01-22 | Dignity Sciences Ltd | Omega-6 Enriched PUFA Phospholipids |
| WO2014022816A2 (en) | 2012-08-03 | 2014-02-06 | Dignity Sciences Limited | Pharmaceutical compositions comprising 15-hetre and methods of treating or preventing arthritis using same |
| GB201216385D0 (en) * | 2012-09-13 | 2012-10-31 | Chrysalis Pharma Ag | A pharmaceutical composition |
| US9682055B2 (en) * | 2014-06-04 | 2017-06-20 | Dignity Sciences Limted | Pharmaceutical compositions comprising DGLA and use of same |
| MA47141A (fr) | 2015-05-13 | 2019-11-06 | Ds Biopharma Ltd | Compositions comprenant du15-oxo-epa ou du 15-oxo-dgla et leurs procédés de préparation et d'utilisation |
| CA3027867A1 (en) | 2016-01-07 | 2017-07-13 | Ds Biopharma Limited | Pharmaceutical compositions comprising dgla and use of same |
-
2015
- 2015-06-04 US US14/730,818 patent/US9682055B2/en not_active Expired - Fee Related
- 2015-06-04 CN CN201580039328.7A patent/CN107072959A/zh active Pending
- 2015-06-04 MA MA052644A patent/MA52644A/fr unknown
- 2015-06-04 EP EP20153902.0A patent/EP3692986A1/en not_active Withdrawn
- 2015-06-04 KR KR1020177000244A patent/KR102391827B1/ko not_active Expired - Fee Related
- 2015-06-04 ES ES15727395T patent/ES2784240T3/es active Active
- 2015-06-04 RU RU2020101477A patent/RU2020101477A/ru unknown
- 2015-06-04 SG SG11201610207WA patent/SG11201610207WA/en unknown
- 2015-06-04 BR BR112016028518A patent/BR112016028518A2/pt not_active IP Right Cessation
- 2015-06-04 RU RU2016151719A patent/RU2714323C2/ru active
- 2015-06-04 MX MX2016015961A patent/MX375328B/es active IP Right Grant
- 2015-06-04 WO PCT/EP2015/062518 patent/WO2015185698A1/en not_active Ceased
- 2015-06-04 AU AU2015270418A patent/AU2015270418B2/en not_active Ceased
- 2015-06-04 CA CA2953633A patent/CA2953633A1/en not_active Abandoned
- 2015-06-04 SG SG10201912145VA patent/SG10201912145VA/en unknown
- 2015-06-04 JP JP2016570986A patent/JP2017516823A/ja active Pending
- 2015-06-04 EP EP15727395.4A patent/EP3151825B1/en active Active
-
2016
- 2016-11-04 US US15/343,689 patent/US20170071890A1/en not_active Abandoned
- 2016-12-02 MX MX2020009709A patent/MX2020009709A/es unknown
- 2016-12-04 IL IL249364A patent/IL249364B/en active IP Right Grant
- 2016-12-16 PH PH12016502530A patent/PH12016502530A1/en unknown
-
2017
- 2017-07-27 US US15/661,374 patent/US10105333B2/en active Active
- 2017-12-14 US US15/842,194 patent/US20180104208A1/en not_active Abandoned
- 2017-12-20 ZA ZA2017/08681A patent/ZA201708681B/en unknown
-
2018
- 2018-03-26 US US15/935,739 patent/US20180214408A1/en not_active Abandoned
- 2018-12-13 ZA ZA2018/08414A patent/ZA201808414B/en unknown
-
2019
- 2019-02-19 US US16/279,819 patent/US10537543B2/en not_active Expired - Fee Related
- 2019-02-19 US US16/279,794 patent/US20190269639A1/en not_active Abandoned
- 2019-11-08 US US16/678,431 patent/US10849870B2/en not_active Expired - Fee Related
-
2020
- 2020-01-14 JP JP2020003665A patent/JP2020090508A/ja not_active Withdrawn
- 2020-06-24 US US16/910,770 patent/US11478442B2/en active Active
- 2020-10-28 AU AU2020260433A patent/AU2020260433A1/en not_active Abandoned
-
2021
- 2021-02-07 IL IL280690A patent/IL280690A/en unknown
-
2022
- 2022-03-01 JP JP2022030554A patent/JP2022071061A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017516823A5 (https=) | ||
| US20240016803A1 (en) | Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin | |
| JP2022062151A5 (https=) | ||
| HRP20201830T1 (hr) | Stabilni farmaceutski sastav i metode njegove upotrebe | |
| RU2016151719A (ru) | Фармацевтические композиции, содержащие дглк, и их применение | |
| JP2019501190A5 (https=) | ||
| FI3750535T3 (fi) | Menetelmiä sydän- ja verisuonitautitapahtumien riskin vähentämiseksi tutkittavalla | |
| KR20120104270A (ko) | 심혈관계 질환 치료에 유용한 복합 조성물 | |
| US20180169050A1 (en) | Enhanced Bioavailability of Polyunsaturated Fatty Acids | |
| JP2020090508A5 (https=) | ||
| Chadda et al. | Bradycardia-hypotension syndrome in acute myocardial infarction: reappraisal of the overdrive effects of atropine | |
| DE4340879A1 (de) | Arzneimittel zur Behandlung der Herzinsuffizienz | |
| Burch et al. | Prolonged bed rest in the treatment of ischemic cardiomyopathy | |
| CA2950444C (en) | Enhanced bioavailability of polyunsaturated fatty acids | |
| CN115137747B (zh) | 多聚水杨酸在治疗急性心肌梗死中的应用 | |
| Ghosh et al. | Chronotherapeutic drug delivery: A way forward to treat rhythm guided diseases | |
| Ahuja et al. | To PLEX or Not to PLEX for Amiodarone‐Induced Thyrotoxicosis | |
| CN104382914B (zh) | 磷酸肌酸二钠盐在制备稳定和消退动脉粥样硬化斑块药物中的应用 | |
| Liu et al. | Catheter ablation of ventricular arrhythmias originating from the pulmonary sinus cusp in pediatric patients: a single-center retrospective study | |
| Walker et al. | Acute effects of ketanserin on left ventricular function, metabolism and coronary blood flow. | |
| Maronde | Case reports of two primary cardiac neoplasms | |
| CN102516166A (zh) | 一种非诺贝特的烟酸类衍生物及其制备方法 | |
| Herman et al. | Recurrent ventricular tachycardia as the chief manifestation of myocarditis of unknown etiology | |
| CN103432128B (zh) | 一种盐酸吡格列酮缓释微丸制剂含药层的组配方法 | |
| RU2023110518A (ru) | Стабильные фармацевтические композиции и способы их применения |